The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries

Coronary Artery Disease Clinical Trial

— BIOADAPTOR RCT  

Official title:

Evaluation of a Sirolimus Eluting Bioadaptor as Compared to a Zotarolimus Eluting Stent in De Novo Native Coronary Arteries ELX-CL-1805

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04192747
• Other study ID #: ELX-CL-1805
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 16, 2020
• Est. completion date: February 28, 2027

Study information

• Verified date: September 2023
• Source: Elixir Medical Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to verify the safety and efficacy of the investigational device (ELX1805J) for the treatment of ischemic heart disease due to de novo, native coronary artery lesions

Description:

The Bioadaptor RCT Study is a prospective, 1:1 randomized study of parallel designed, that will enroll up to 444 patients requiring treatment of up to two de novo coronary lesions of ≤ 34 mm in length in vessels of ≥ 2.25 mm and ≤ 4.0 mm in diameter.

One or two designated target lesions, located in separate epicardial vessels (RCA, LCX or LAD), and meeting the inclusion/exclusion criteria may be treated with the ELX1805J (DynamX Bioadaptor) or Resolute Onyx stent

The primary safety endpoint is Target Lesion Failure (TLF) at 12 months. TLF is a composite endpoint defined as cardiac death, target vessel MI, and clinically-indicated target lesion revascularization

Additional secondary safety and effectiveness endpoints will be evaluated at 30 days, 6 and 12 months and 2-5 years.

Using visual assessment, the target lesion must measure ≥ 2.25 mm and ≤ 4.0 mm in diameter and ≤ 34 mm in length able to be covered by a single ELX1805J or Resolute Onyx stent including 2 mm of healthy vessel on either side of the planned treatment area.

The patient will be eligible for device implantation only after satisfactory lesion pre-dilatation defined as: ≥ TIMI 2 flow, and no dissection greater than Grade B (NHLBI) able to be covered with a single device

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 444
• Est. completion date: February 28, 2027
• Est. primary completion date: February 28, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

General Inclusion Criteria

Patients who meet all of the following criteria are eligible:

1. Patient must be = 20 years of age.

2. Patient must have evidence of myocardial ischemia (e.g., stable or unstable angina, silent ischemia, positive functional study or electrocardiogram (ECG) changes consistent with ischemia)

3. Patients who are able to take dual anti-platelet therapy for 1 year following the index procedure and anticoagulants prior to/during the index procedure.

4. The subject is an acceptable candidate for Percutaneous Transluminal Coronary Angioplasty (PTCA), stenting, and emergent Coronary Artery Bypass Graft (CABG) surgery.

5. The subject or subject's legally authorized representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board or Ethics Committee of the respective clinical site.

6. Women of childbearing potential with a negative pregnancy test within 7 days and women who are not pregnant or nursing

7. Patient must agree to undergo all clinical study required follow up visits, angiograms, and imaging testing

8. Patient must agree not to participate in any other clinical research study for a period of one year following the index procedure

9. Target lesion(s) must be de novo and located in a native coronary artery with a vessel mean diameter of = 2.25 and = 4.0 mm.

10. Target lesion(s) must be in a major artery or branch with a visually estimated stenosis of = 50% and < 100% with a TIMI flow of > 1. When two target lesions are treated, they must be located in separate major epicardial vessels

11. visually estimated target lesion length is = 34mm mm and must be able to be covered by a single 14/15/18/23/28/32/38 mm ELX1805J stent and have at least 2 mm of healthy vessel on either side Or

12. The visually estimated target lesion length is = 34mm mm and must be able to be covered by a single 15/18/22/30/34/38 mm ZES stent respectively and have at least 2 mm of healthy vessel on either side.

13. The lesion(s) must be successfully pre-dilated prior to enrollment Mandatory pre-dilatation includes the use of 2 orthogonal views to confirm lesion inclusion and exclusion criteria and successful pre-dilatation defined as balloon inflation without waist and a lumen diameter no less than 0.5 mm smaller than the vessel diameter.

14. Percutaneous intervention of lesions in a non-target vessel if:

• Not part of a another clinical investigation

• = 30 days prior to the study index procedure

• = 6 months after the study index procedure (planned)

15. Percutaneous intervention of lesions located in the target vessel if:

• Not part of a clinical investigation

• = 6 months prior to the study index procedure

• >12 months after the study index procedure (planned)

• Previous intervention was distal to and >10 mm from the target lesion

Exclusion Criteria:

1. The patient was diagnosed with an acute myocardial infarction within the past 72 hours and the CK and CKMB have not returned to normal (or cTn >15x ULN) and the patient is experiencing clinical symptoms indicative of ongoing ischemia

2. Patient has a known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, clopidogrel, prasugrel or ticagrelor, cobalt, nickel, chromium, molybdenum, PLLA polymers or contrast sensitivity that cannot be adequately pre-medicated

3. Patients with a history of allergic reaction or serious hypersensitivity to drugs exhibiting interactions with sirolimus, zotarolimus, everolimus, tacrolimus, temsirolimus, biolimus and other rapamycin, derivatives or analogues) or similar drugs

4. Elective surgery is planned within the first 6 months after the procedure that will require discontinuing either aspirin or clopidogrel or other P2Y12 inhibitors.

5. Patient presenting with chronic (permanent) atrial or ventricular arrhythmia or current unstable ventricular arrhythmias

6. Patient has a known left ventricular ejection fraction (LVEF) < 30%

7. Patient has received a heart or other organ transplant or is on a waiting list for any organ transplant

8. Patient has a malignancy that is not in remission.

9. Patient is receiving immunosuppression therapy other than steroids and has known immunosuppressive or autoimmune disease (e.g. human immunodeficiency virus, systemic lupus erythematosus etc.)

10. Patient is receiving chronic anticoagulation therapy (e.g., heparin, coumadin) that cannot be stopped and restarted according to local hospital standard procedures.

11. Patient has a platelet count < 100,000 cells/mm3 or > 700,000 cells/mm3, a WBC of < 3,000 cells/mm3, or documented or suspected to have cirrhosis of Child-Pugh = Class B within 7 days before study procedure

12. Patient has known renal insufficiency (e.g., serum creatinine level of more than 2.5 mg/dL within 7 days before study procedure, or patient on dialysis)

13. Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions

14. Patient has had a cerebrovascular accident (CVA) or transient ischemic neurological attack (TIA) within the past six months

15. Patient has had a significant GI or urinary bleed within the past six months

16. Patient has severe symptomatic heart failure (i.e., NYHA class IV)

17. Patient has a medical condition that precludes safe 6 French sheath insertion

18. Patient has other medical illness or known history of substance abuse (alcohol, cocaine, heroin etc.) that may cause non-compliance with the clinical study plan, confound the data interpretation or is associated with a limited life expectancy (i.e., less than one year)

19. Patient is already participating in another clinical research study which has not reached the primary endpoint (long-term follow-up is not an exclusion)

20. Other patients whom primary investigator or subinvestigator determined to be ineligible for this clinical study

21. Patients with bypass graft to the target vessel or lesion is located in a bypass graft

22. Patients with stent implanted within 10 mm of proximal or distal end of target lesion

23. Patients with a target lesion involving a bifurcation of which the side branch will be jailed by the struts and:

• Side branch = 2.5 mm in diameter,

• Side branch requiring predilatation (including Kissing Balloon Technique), or

• Side branch has an ostial lesion or lesion with > 50% stenosis

24. Patients suspected or confirmed with the QCA analysis of having stenotic lesion of more than 50% in target vessel in addition to target lesion

25. Patients with target lesion in ostia located within 5 mm of origin of LAD, LCX or RCA

26. Patients with stenotic lesion in left main trunk

27. Patients with target lesion that is a chronic total occlusion (CTO) or = TIMI 1 coronary flow in the target vessel

28. Patients with target vessel that contains thrombus as indicated in pre-procedure angiographic, IVUS or OCT images

29. Excessive tortuosity = two 45° angles or extreme angulation (= 90°) proximal to or within the target lesion

30. Patients with target vessel that has moderate to severe calcification that prevents complete angioplasty balloon (POBA with non-compliant balloon, or scoring balloon,) inflation or requires other devices such as rotational atherectomy, rotoblator.

31. Patients with dissection of Grade A or B that cannot be covered (including 2mm distal to the dissection) with a single study device or with dissection of Grade C or higher

32. Patients with 2 or more target lesions on 1 branch or target lesions on 3 branches that need to be treated during study procedure

33. Target lesion involves a myocardial bridge

Related Conditions & MeSH terms

• Constriction, Pathologic
• Coronary Artery Disease
• Coronary Artery Stenosis
• Coronary Disease
• Coronary Stenosis

Intervention

Device:
• Percutaneous Coronary Intervention
Percutaneous coronary intervention of de novo native coronary artery lesions

Locations

Country	Name	City	State
Belgium	AZ Middelheim Hospital	Antwerp
Belgium	AZ Sint Jan Brugge	Brugge
Belgium	Ziekenhuis Oost-Limburg	Genk
Belgium	Universitaire Ziekenhuizen Leuven	Leuven
Germany	Kerkhoff Klinik GmbH	Bad Nauheim
Germany	Segeberger Kliniken GmbH	Bad Segeberg
Germany	REGIOMED Klinikum Coburg	Coburg
Germany	St. Johannes Hospital	Dortmund
Germany	Universitatsklinikum Erlangen	Erlangen
Germany	Elisabeth Krankenhaus Essen	Essen
Germany	MVZ CCB Frankfurt	Frankfurt
Germany	Universitatsklinikun Giessen	Giessen
Germany	Universitätsklinikum Jena	Jena
Germany	UKSH Kiel Klinik	Kiel
Germany	Universitätsmedizin-Mainz	Mainz
Germany	Krankenhaus der barmherzigen Bruder	Trier
Japan	Oumi Hachiman City General Medical Center	Hachiman	Shiga-Ken
Japan	Tenyokai Central Hospital	Kagoshima City	Kagoshima-Ken
Japan	Shonan Kamakura General Hospital	Kamakura City,	Kanagawa-Ken
Japan	Kanto Rosai Hospital	Kawasaki-shi	Kanagawa-Ken
Japan	Kokura Memorial Hospital	Kitakyushu City	Fukuoka-Ken
Japan	Kumamoto Rousai Hospital	Kumamoto	Kumamoto-Ken
Japan	Shinkoga Hospital	Kurume City	Fukuoka-Ken
Japan	Miyazaki Medical Association Hospital	Miyazaki City	Miyazaki-Ken
Japan	Sapporo Higashi Tokushukai Hospital	Sapporo	Hokkaido
Japan	Cardiovascular Reaearch Institute	Tokyo
Japan	Teikyo University Hospital	Tokyo
Japan	Takahashi Hospital	Tsuchiura City	Ibaraki-Ken
Japan	Tsuchiura Kyodo Hospital	Tsuchiura City	Ibaraki-Ken
Japan	Yokohama City Eastern Hospital	Yokohama-shi	Kanagawa-Ken
New Zealand	Auckland City Hospital	Auckland
New Zealand	Middlemore Clinical Trials Trust	Auckland
New Zealand	Waikato Hospital	Auckland
New Zealand	Christchurch Hospital	Christchurch
New Zealand	Dunedin Hospital	Dunedin
New Zealand	North Shore Hospital	Takapuna

Sponsors (1)

Lead Sponsor	Collaborator
Elixir Medical Corporation

Countries where clinical trial is conducted

Belgium,  Germany,  Japan,  New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients with Target Lesion Failure (TLF)	TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated	12 Months
Secondary	Number of Patients with Target Lesion Failure (TLF)	TLF is a composite endpoint defined as cardiac death, target-vessel MI, and Clinically-Indicated	30 Days, 180 Days, 2, 3, 4 and 5 years
Secondary	Number of Patients with Patient Oriented Clinical Endpoint	Overall cardiovascular outcomes from the patient's perspective. This endpoint is a composite endpoint that includes all-cause mortality (cardiac and non-cardiac), stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of All-cause mortality	A composite of all-cause mortality, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of Cardiac Death TVMI and ID-TVR revascularization	Composite of cardiac death, target vessel myocardial infarction (TV-MI), or ischemia-driven target vessel revascularization (ID-TVR)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Cardiac death, stroke, MI and revascularization	Composite of cardiac death, stroke, MI (target vessel and non-target vessel) and revascularization (target vessel and non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Cardiac death, MI and revascularization	Composite of cardiac death, MI (target vessel or non-target vessel) and revascularization (target vessel or non-target vessel)	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Ischemia Driven Target Lesion Revascularization (ID-TLR)	Ischemia driven target lesion revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Target Lesion Revascularization (TLR)	Target lesion revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Target Vessel Revascularization (TVR)	Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Ischemia driven TVR (ID-TVR)	Re-PCI or CABG in the target vessel due to restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Revascularization (target vessel or non-target vessel)	Re-PCI or CABG of the target vessel due to in-segment restenosis or other complications	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Q-wave MI	CK post procedure is twice the upper limit of the reference value or higher, with new pathological Q-wave on 2 or more contiguous ECG leads and if CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Non Q-wave MI	CK post procedure is twice the upper limit of the reference value or higher, without new pathological Q-waves. If CK-MB is measured, CK-MB is positive, if no CKMB then troponin is positive.	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with MI (target vessel or non-target vessel)	per ARC II	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Target Vessel MI	per ARC II	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with All-cause Death	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Cardiac Death	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of Cardiac Death or Target Vessel MI	Target Vessel Related Death or MI	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of all-cause Death or MI	target vessel or non-target vessel related death or MI	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of all-cause Death, MI (target vessel or non-target vessel), or TVR	Any Death, any MI and any Target Vessel Revascularization	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Composite of Probable or Definite Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Probable Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years
Secondary	Number of Patients with Definite Stent Thrombosis	Per ARC II Definitions	30 Days, 180 Days, 1, 2, 3, 4 and 5 years